Home
|
Help
|
Contact
Sign in
WPRIM Management System>
DCMS
>
Protein & Cell
>
2018
>
9
>
1
Volume:
9
Issue:
1
1. Current progress in innovative engineered antibodies.
Page:86—120
2. Molecular and functional analysis of monoclonal antibodies in support of biologics development.
Page:74—85
3. A novel therapeutic anti-HBV antibody with increased binding to human FcRn improves in vivo PK in mice and monkeys.
Page:130—134
4. Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy.
Page:47—62
5. Potent and conditional redirected T cell killing of tumor cells using Half DVD-Ig.
Page:121—129
6. Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab.
Page:135—139
7. Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins.
Page:15—32
8. In vitro-engineered non-antibody protein therapeutics.
Page:3—14
9. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
Page:33—46
10. "Magic Bullets" at the center stage of immune therapy: a special issue on therapeutic antibodies.
Page:1—2
11. IgG Fc engineering to modulate antibody effector functions.
Page:63—73